| Literature DB >> 33483496 |
Yang Zhang1, Xiaofang Zhang1, Benzhi Cai1, Ying Li1, Yuan Jiang1, Xiaoyu Fu1, Yue Zhao1, Haiyu Gao1, Ying Yang1, Jiming Yang1, Shangxuan Li1, Hao Wu1, Xuexin Jin1, Genlong Xue1, Jiqin Yang1, Wenbo Ma1, Qilong Han1, Tao Tian1, Yue Li2,3, Baofeng Yang4,5, Yanjie Lu1, Zhenwei Pan6,7.
Abstract
Cardiac ischemia-reperfusion (I/R) injury is a pathological process resulting in cardiomyocyte death. The present study aims to evaluate the role of the long noncoding RNA Cardiac Injury-Related Bclaf1-Inhibiting LncRNA (lncCIRBIL) on cardiac I/R injury and delineate its mechanism of action. The level of lncCIRBIL is reduced in I/R hearts. Cardiomyocyte-specific transgenic overexpression of lncCIRBIL reduces infarct area following I/R injury. Knockout of lncCIRBIL in mice exacerbates cardiac I/R injury. Qualitatively, the same results are observed in vitro. LncCIRBIL directly binds to BCL2-associated transcription factor 1 (Bclaf1), to inhibit its nuclear translocation. Cardiomyocyte-specific transgenic overexpression of Bclaf1 worsens, while partial knockout of Bclaf1 mitigates cardiac I/R injury. Meanwhile, partial knockout of Bclaf1 abrogates the detrimental effects of lncCIRBIL knockout on cardiac I/R injury. Collectively, the protective effect of lncCIRBIL on I/R injury is accomplished by inhibiting the nuclear translocation of Bclaf1. LncCIRBIL and Bclaf1 are potential therapeutic targets for ischemic cardiac disease.Entities:
Year: 2021 PMID: 33483496 PMCID: PMC7822959 DOI: 10.1038/s41467-020-20844-3
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919